Scholarlink

Objective <p>While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab.</p> Methods <p>Data was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch.</p> Results <p> In total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation (<i>n</i> = 74, 79%), which reduced to only 12% (<i>n</i> = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period.</p> Conclusion <p>Switching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Faisal Mohammad Amin,
  • Thor Linnet,
  • Christopher Kjaer Cullum,
  • Thien Phu Do,
  • Samaira Younis

摘要

Objective

While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab.

Methods

Data was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch.

Results

In total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation (n = 74, 79%), which reduced to only 12% (n = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period.

Conclusion

Switching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments.